首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1447809

全球靜脈注射免疫球蛋白市場規模、佔有率、成長分析、依應用（低丙種球蛋白血症、CIDP）、依類型（IgG、IgM）、依配銷通路（醫院藥房、專業藥房）-2024-2031 年產業預測

Global Intravenous Immunoglobulin Market Size, Share, Growth Analysis, By Application(Hypogammaglobulinemia, CIDP), By Type(IgG, IgM), By Distribution Channel(Hospital Pharmacy, Specialty Pharmacy) - Industry Forecast 2024-2031

出版日期: 2024年02月27日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球靜脈免疫球蛋白市場規模為119.8億美元，預計將從2023年的128.5億美元成長到2031年的225.9億美元，在預測期內（2024-2031年）複合CAGR為7.3%。

全球靜脈注射免疫球蛋白 (IVIG) 市場受到一些主要因素的推動，例如老年人口的成長、免疫缺陷疾病的增加、IVIG 治療的標籤外適應症的使用增加以及 IVIG 療法的日益採用。越來越多的免疫系統缺陷患者仍然是 IVIG 供應的創造和需求背後的關鍵力量。越來越多的患者面臨出血問題和慢性發炎性脫髓鞘多發性神經病變（CIDP），促使這個全球市場的快速成長。由於醫療保健行業投資增加，IVIG 市場正在成長。此外，自體免疫疾病和其他病理狀況的日益普及是 IVIG 產品市場不斷成長的一個主要因素，凸顯了它們在滿足一系列醫療需求方面的關鍵作用。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

Grifols SA
Octapharma AG
ADMA Biologics
LFB Biotechnologies
Kedrion Biopharma,
Intas Pharmaceuticals.
Biotest AG
BDI Pharma Inc.
Shanghai RAAS Blood Products Co., Ltd.
Takeda Pharmaceutical Company Limited.
CSL Behring
Baxter International Inc.
China Biologics Products Inc.

簡介目錄

Product Code: SQMIG35A2611

Global Intravenous Immunoglobulin Market size was valued at USD 11.98 billion in 2022 and is poised to grow from USD 12.85 billion in 2023 to USD 22.59 billion by 2031, growing at a CAGR of 7.3% during the forecast period (2024-2031).

The Global Intravenous Immunoglobulin (IVIG) Market is being driven by some major factors like the growing elderly population, an increase in immunodeficiency disorders, the increased usage of off-label indications for IVIG treatments, and the increasing adoption of IVIG therapies. The increasing number of individuals with immune system deficiencies continues to be the key force behind the creation and need for IVIG supplies. The increasing number of patients dealing with bleeding problems and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is leading to the rapid growth of this global market. The IVIG market is growing as a result of the increased investments made in the healthcare industry. Furthermore, the increasing prevalence of autoimmune diseases and other pathological conditions is a major factor in the growing market for IVIG products, highlighting their critical role in meeting a range of medical needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Intravenous Immunoglobulin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Intravenous Immunoglobulin Market Segmental Analysis

Four segments make up the worldwide intravenous immunoglobulin market: those based on application, type, distribution channel, and region. The market is divided into several segments based on the application, including Hypogammaglobulinemia, Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Guillain-Barre Syndrome, Kawasaki Disease, and Others. The market is divided into IgG, IgM, IgA, IgE, and IgD segments based on type. The market is divided into Hospital Pharmacy, Specialty Pharmacy, and others segments based on the distribution channel. The market is divided into three regions: North America, Asia Pacific, and Latin America.

Drivers of the Global Intravenous Immunoglobulin Market

One of the main factors driving the growth of the intravenous immunoglobulin market is the widespread adoption of IVIG as the primary treatment option for a variety of uncommon immunological and neurological disorders, most notably primary immunodeficiency (PI) and related diseases. IVIG therapy's widespread adoption as the primary treatment for these illnesses attests to its relevance and effectiveness in controlling them.

Restraints in the Global Intravenous Immunoglobulin Market

Demyelinating illnesses come with a significant financial burden due to diagnosis and treatment costs. One prominent factor impeding the market's growth is the increasing expenses associated with IVIG treatment. IVIG infusions are recurrent, usually given every 3-4 weeks; there are roughly 12-16 sessions per year. IVIG is expected to cost USD 73.89 per gram, for a total anticipated cost of approximately USD 10,000.

Market Trends of the Global Intravenous Immunoglobulin Market

A number of significant trends are influencing the market's evolution and redefining its growth and advancement trajectory. Among them, the most notable trend in the treatment of neurological illnesses is the increasing use of intravenous immunoglobulin (IVIG), which underscores the drug's expanding use outside its conventional applications. Furthermore, a significant change in IVIG therapy is the application of personalized medicine concepts, which allow for the customization of treatments to meet the specific needs of each patient. The development of new immunomodulatory therapies is also reshaping the field and opening up new therapeutic options.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Intravenous Immunoglobulin Market by Application

Market Overview
Hypogammaglobulinemia
CIDP
Immunodeficiency Diseases
Congenital AIDS
Chronic Lymphocytic Leukemia
Myasthenia Gravis
Multifocal Motor Neuropathy
ITP
Kawasaki Disease
Guillain-Barre Syndrome
and Others

Global Intravenous Immunoglobulin Market by Type

Market Overview
IgG
IgM
IgA
IgE
and IgD

Global Intravenous Immunoglobulin Market by Distribution Channel

Market Overview
Hospital Pharmacy
Specialty Pharmacy
and Others

Global Intravenous Immunoglobulin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Grifols SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADMA Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion Biopharma,
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intas Pharmaceuticals.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotest AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BDI Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai RAAS Blood Products Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China Biologics Products Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments